Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KISS1R | Q969F8 | 4/20 | 0.45 |
| ▸ | NPY4R | P50391 | 10/20 | 0.43 |
| ▸ | NPY1R | P25929 | 7/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.43 |
| ▸ | NPY2R | P49146 | 4/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20715753 | 1.00 | KISS1R (0.45) | KISS1RNPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL24324975 | 0.91 | NPY4R (0.45) | KISS1RNPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL24340680 | 0.88 | KISS1R (0.46) | KISS1RNPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL24340468 | 0.88 | KISS1R (0.46) | KISS1RNPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL19234644 | 0.87 | KISS1R (0.45) | KISS1RNPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29511585 | 0.80 | NPY4R (0.53) | KISS1RNPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL13224352 | 0.80 | FURIN (0.47) | NPY4RNPY1RNPY5RNPY2ROPRK1 | |
| SCHEMBL24340682 | 0.79 | NPY4R (0.44) | KISS1RNPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL20715848 | 0.79 | NPY4R (0.46) | KISS1RNPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL24325253 | 0.79 | NPY4R (0.43) | NPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11279732-B2 | Somatostatin receptor antagonist compounds and methods of using the same | CDRD VENTURES INC. (CA) | 2022-03-22 | — | — | US | disclosed |
| US-20190040102-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | CDRD VENTURES INC. (CA) | 2019-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11279732-B2 | Somatostatin receptor antagonist compounds and methods of using the same | GPR119, SSTR5, SSTR2 | KISS1R 58/4885NPY4R 31/4885NPY1R 21/4885 |
| US-20190040102-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | GPR119, SSTR5, SSTR2 | KISS1R 58/4885NPY4R 31/4885NPY1R 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.